Five-Year Outcomes After Paclitaxel Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Diabetic and Chronic Limb-Threatening Ischemia Cohorts: IN.PACT Global Study Post Hoc Analysis

Overview

Journal Cardiovasc Intervent Radiol

Specialty Cardiology & Vascular Diseases

Date 2023 Aug 1

PMID 37526706

Authors

Michel M P J Reijnen

Iris van Wijck

Marianne Brodmann

Antonio Micari

Giovanni Torsello

Seung-Woon Rha

Jeremiah Menk

Thomas Zeller

Affiliations

Soon will be listed here.

Abstract

Purpose: To summarize the 5-year outcomes of drug-coated balloon (DCB) for the treatment of femoropopliteal lesions in patients with diabetes mellitus (DM) or chronic limb-threatening ischemia (CLTI) compared to non-DM and intermittent claudication (IC).

Methods: The IN.PACT Global study was a real-world prospective, multicenter, international, single-arm study that enrolled 1535 participants. Post hoc analyses were conducted for participants with DM (n = 560) versus non-DM (n = 842) and CLTI (n = 156) versus IC (n = 1246). Assessments included freedom from clinically driven target lesion revascularization (CD-TLR) through 60 months, a composite safety outcome (freedom from device- and procedure-related death through 30 days, and freedom from major target limb amputation and freedom from CD-target vessel revascularization within 60 months), and major adverse events (MAEs).

Results: Kaplan-Meier estimates of 60-month freedom from CD-TLR were 67.7% and 70.5% (p = 0.25) in the DM and non-DM cohorts; and 60.7% and 70.5% (p = 0.006) in the CLTI and IC cohorts. The Kaplan-Meier 60-month composite safety outcomes were 65.1% DM versus 68.9% non-DM (p = 0.12); 53.2% CLTI versus 69.1% IC (p < 0.001). Between DM and non-DM, MAE rates were not significantly different through 60 months except for all-cause mortality which was higher in DM (23.8% versus 16.6%; p < 0.001). Participants with CLTI had a higher cumulative incidence of major target limb amputation (6.8% versus 1.1%; p < 0.001) and all-cause mortality (37.4% versus 17.4%; p < 0.001) through 60 months compared to IC.

Conclusions: In this real-world study, 5-year reintervention rates following DCB angioplasty were similar between DM and non-DM, but mortality rates were expectedly higher in patients with DM. Reintervention, mortality, and amputation rates were all higher in CLTI patients compared to IC, which is consistent with the known frailty of this patient population.

Level Of Evidence: Level 3, Non-randomized controlled cohort/follow-up study.

Citing Articles

Long-term Outcome with Paclitaxel Drug-coated Balloon in the Real World: Focus on Those Most at Risk.

Teichgraber U Cardiovasc Intervent Radiol. 2023; 46(10):1346-1347.

PMID: 37750920 PMC: 10547608. DOI: 10.1007/s00270-023-03556-1.

References

Chen Z, Guo W, Jiang W, Wang F, Fu W, Zou Y . IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population. J Endovasc Ther. 2019; 26(4):471-478. PMC: 6630064. DOI: 10.1177/1526602819852084. View

Conte M, Bradbury A, Kolh P, White J, Dick F, Fitridge R . Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019; 69(6S):3S-125S.e40. PMC: 8365864. DOI: 10.1016/j.jvs.2019.02.016. View

Lee M, Choi B, Rha S . Impact of diabetes mellitus on 5-year clinical outcomes following successful endovascular revascularization for peripheral artery disease. Vasc Med. 2019; 25(1):33-40. DOI: 10.1177/1358863X19879751. View

Duff S, Mafilios M, Bhounsule P, Hasegawa J . The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag. 2019; 15:187-208. PMC: 6617560. DOI: 10.2147/VHRM.S209241. View

Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F . Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial. JACC Cardiovasc Interv. 2016; 9(18):1941-9. DOI: 10.1016/j.jcin.2016.06.055. View

Zeller T, Brodmann M, Micari A, Keirse K, Peeters P, Tepe G . Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. Circ Cardiovasc Interv. 2019; 12(1):e007730. DOI: 10.1161/CIRCINTERVENTIONS.118.007730. View

Mueller T, Hinterreiter F, Luft C, Poelz W, Haltmayer M, Dieplinger B . Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. J Vasc Surg. 2014; 59(5):1291-9. DOI: 10.1016/j.jvs.2013.11.063. View

Spreen M, Gremmels H, Teraa M, Sprengers R, Verhaar M, Statius van Eps R . Diabetes Is Associated With Decreased Limb Survival in Patients With Critical Limb Ischemia: Pooled Data From Two Randomized Controlled Trials. Diabetes Care. 2016; 39(11):2058-2064. DOI: 10.2337/dc16-0850. View

Laird J, Schneider P, Jaff M, Brodmann M, Zeller T, Metzger D . Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circ Cardiovasc Interv. 2019; 12(6):e007702. PMC: 6636795. DOI: 10.1161/CIRCINTERVENTIONS.118.007702. View

10.

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A . Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2014; 131(5):495-502. PMC: 4323569. DOI: 10.1161/CIRCULATIONAHA.114.011004. View

11.

Scheinert D, Schulte K, Zeller T, Lammer J, Tepe G . Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015; 22(1):14-21. DOI: 10.1177/1526602814564383. View

12.

Aboyans V, Ricco J, Bartelink M, Bjorck M, Brodmann M, Cohnert T . 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric,.... Eur Heart J. 2017; 39(9):763-816. DOI: 10.1093/eurheartj/ehx095. View

13.

Thiruvoipati T, Kielhorn C, Armstrong E . Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes. 2015; 6(7):961-9. PMC: 4499529. DOI: 10.4239/wjd.v6.i7.961. View

14.

Pietzsch J, Geisler B, Iken A, van Wijck I, Holewijn S, Reijnen M . Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany. Cardiovasc Intervent Radiol. 2022; 45(3):298-305. DOI: 10.1007/s00270-021-03050-6. View

15.

Soga Y, Iida O, Urasawa K, Saito S, Jaff M, Wang H . Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty. J Endovasc Ther. 2020; 27(6):946-955. PMC: 7649941. DOI: 10.1177/1526602820948240. View

16.

Xu Y, Liu J, Zhang J, Zhuang B, Jia X, Fu W . Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial. J Vasc Surg. 2021; 74(3):756-762.e3. DOI: 10.1016/j.jvs.2021.01.041. View

17.

Bradbury A, Moakes C, Popplewell M, Meecham L, Bate G, Kelly L . A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal.... Lancet. 2023; 401(10390):1798-1809. DOI: 10.1016/S0140-6736(23)00462-2. View

18.

Farber A, Menard M, Conte M, Kaufman J, Powell R, Choudhry N . Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. N Engl J Med. 2022; 387(25):2305-2316. DOI: 10.1056/NEJMoa2207899. View

19.

Micari A, Brodmann M, Keirse K, Peeters P, Tepe G, Frost M . Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study. JACC Cardiovasc Interv. 2018; 11(10):945-953. DOI: 10.1016/j.jcin.2018.02.019. View

20.

Vrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M . Impact of diabetes on mortality in peripheral artery disease: a meta-analysis. Clin Cardiol. 2016; 40(5):287-291. PMC: 6490626. DOI: 10.1002/clc.22657. View